Dr. Lal PathLabs Q4 FY26 Revenue at ₹703 Crore, Up 16.6%; FY26 Revenue ₹2,763 Crore
Dr. Lal PathLabs reported Q4 FY26 revenue of ₹703 crore (up 16.6%) and FY26 revenue of ₹2,763 crore (up 12.2%). EBITDA for FY26 was ₹752 crore. The company plans ₹100-₹120 crore capex in FY27. A final dividend of 40% was approved. The company expects early to mid-teens revenue growth in FY27.
The announcement includes detailed financial results for the quarter and the full year, significant growth figures, dividend declaration, and future growth guidance, all of which are material information for investors and analysts, impacting the company's valuation and investor sentiment.
The company reported strong revenue growth in Q4 and FY26, driven by volume increases. Positive financial metrics like EBITDA and PAT, along with a healthy balance sheet and a proposed dividend, indicate a positive financial performance. Management also expressed confidence in future growth.
Dr. Lal PathLabs Ltd. announced its financial results for the fourth quarter and full fiscal year 2026. The company reported a revenue of ₹703 crore for Q4 FY26, marking a 16.6% increase compared to the same period last year. For the full fiscal year 2026, revenue stood at ₹2,763 crore, a growth of 12.2% over FY25. This performance was primarily driven by an increase in sample volumes, which grew by 12.9% in Q4 and 10.4% in FY26.
The company also highlighted the successful hosting of Medllumina 2026, an international medical conference focused on advanced diagnostics. Operationally, Dr. Lal PathLabs expanded its network by adding 14 new labs and over 1,100 collection centers during the year. The preventive healthcare brand, Swasthfit, contributed 27% to the total revenue in FY26. The company also launched Sovaaka, an AI-powered precision health screening service.
Financially, EBITDA for Q4 FY26 was ₹187 crore (26.6% margin), and for the full year, it was ₹752 crore (27.2% margin). Excluding exceptional items, the adjusted EBITDA margin for FY26 was 28.3%, with a PAT margin of 19.3%. The company maintained a strong balance sheet with net cash and equivalents of ₹1,526 crore. The Board of Directors approved a final dividend of 40% (₹4 per share), bringing the total dividend for the year to ₹20.5 per share (280% after a 1:1 bonus adjustment). Dr. Lal PathLabs expects to sustain early to mid-teens revenue growth in FY27, with a planned capex of ₹100-₹120 crore for the next year, which includes investments in new labs and potentially 1-2 radiology centers.
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.